<SEC-DOCUMENT>0001193125-25-245272.txt : 20251021
<SEC-HEADER>0001193125-25-245272.hdr.sgml : 20251021
<ACCEPTANCE-DATETIME>20251021165939
ACCESSION NUMBER:		0001193125-25-245272
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20251020
FILED AS OF DATE:		20251021
DATE AS OF CHANGE:		20251021

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		251407774

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE
		STREET 2:		264 GEORGE STREET
		CITY:			SYDNEY,
		STATE:			C3
		ZIP:			NSW 2000
		BUSINESS PHONE:		612 8315 7003

	MAIL ADDRESS:	
		STREET 1:		LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE
		STREET 2:		264 GEORGE STREET
		CITY:			SYDNEY,
		STATE:			C3
		ZIP:			NSW 2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d62500d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM&nbsp;6-K </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE&nbsp;13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Date as October 20, 2025 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number&nbsp;001-35428 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact
Name as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#8217;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level&nbsp;32, Australia Square </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>264 George Street, Sydney </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NSW 2000, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant files or will file annual reports under cover of Form&nbsp;20-F or Form&nbsp;40-F. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 20-F&#8194;&#9746;&#8195;&#8195;&#8195;Form 40-F&#8194;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form&nbsp;6-K in paper as permitted by Regulation&nbsp;S-T Rule&nbsp;101(b)(1):&#8194;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form&nbsp;6-K in paper as permitted by Regulation&nbsp;S-T Rule&nbsp;101(b)(7):&#8194;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the
Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&#8194;&#9744;&#8195;&#8195;&#8195;No&#8194;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#8220;Yes&#8221; is marked, indicated below the file number assigned to the registrant in connection with Rule&nbsp;12g3-2(b): Not applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d62500dex991.htm">Two Posters at ESMO Congress 2025 Highlight Immutep&#8217;s Focus on Changing Treatment Landscape in First Line Non-Small Cell Lung Cancer </A></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: October 20, 2025 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d62500dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g62500g05s89.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="center"><B>Two Posters at ESMO Congress 2025 Highlight Immutep&#8217;s Focus on </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="center"><B>Changing Treatment Landscape in First Line <FONT STYLE="white-space:nowrap">Non-Small</FONT> Cell Lung Cancer </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Arial; font-size:10pt"><I>Novel combination of </I><I>efti</I><I> with
KEYTRUDA</I><I><SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP></I><I> and chemotherapy generates strong response rates across all <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression levels in first line
<FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (1L NSCLC) including 61.7% ORR in low</I><I></I><I>&nbsp;&amp; no <FONT STYLE="white-space:nowrap">PD-L1</FONT> (TPS </I><I>&lt;</I><I>50%), well above 40.8% from historical
controls</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Arial; font-size:10pt"><I>Efti&#8217;s ability to expand responders</I><I></I><I>&nbsp;&amp; enhance efficacy with <FONT
STYLE="white-space:nowrap">PD-1</FONT> inhibitors, the best selling class of drugs in oncology, holds great promise to change 1L NSCLC treatment paradigm</I> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="justify"><B>SYDNEY, AUSTRALIA &#8211; October</B><B></B><B>&nbsp;20, 2025 &#8211;</B> <U>Immutep Limited</U> (ASX: IMM; NASDAQ: IMMP) (&#8220;Immutep&#8221; or
&#8220;the Company&#8221;), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces two poster presentations at the European Society for Medical Oncology (ESMO) Congress 2025 highlight the Company&#8217;s focus
on changing the treatment paradigm in first line <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (1L NSCLC). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="justify">Promising data from
the investigator-initiated <FONT STYLE="white-space:nowrap">INSIGHT-003</FONT> trial with a <FONT STYLE="white-space:nowrap">cut-off</FONT> date of 01 September 2025 were detailed in a poster presented by Dr.&nbsp;med. Akin Atmaca, Head of the
Thoracic Oncology, Krankenhaus Nordwest, <FONT STYLE="white-space:nowrap">UCT-University</FONT> Cancer Center, Frankfurt, Germany. In this multi-centre study, the novel combination of eftilagimod alfa (efti) with KEYTRUDA<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (pembrolizumab) and chemotherapy (carboplatin/pemetrexed) has generated strong objective response rates (ORR) and disease control rates (DCR) in 51 evaluable patients with advanced or metastatic <FONT
STYLE="white-space:nowrap">non-squamous</FONT> 1L NSCLC across all <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression levels <I>(see table below).</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="justify">Notably, the ORR and DCR reported in <FONT STYLE="white-space:nowrap">INSIGHT-003</FONT> outperforms historical controls irrespective of <FONT
STYLE="white-space:nowrap">PD-L1</FONT> levels. This is particularly important for patients with low and no <FONT STYLE="white-space:nowrap">PD-L1</FONT> (TPS &lt;50%), who represent over <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the 1L
NSCLC patient population and for whom <FONT STYLE="white-space:nowrap">PD-(L)1</FONT> inhibitors typically perform suboptimally. In patients with TPS &lt;50% (N=47), the combination with efti has achieved a strong and improved 61.7% ORR (with an
additional partial response since 06 May 2025 data cutoff) as compared to historical control of 40.8%.<SUP STYLE="font-size:75%; vertical-align:top">1,2</SUP> </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="center"><B>Efti+KEYTRUDA+Chemo Generates High ORR&nbsp;&amp; DCR Across All <FONT STYLE="white-space:nowrap">PD-L1</FONT> Levels (RECIST 1.1) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:SimHei; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:SimHei; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Arial; "><B>No <FONT STYLE="white-space:nowrap">PD-L1</FONT><BR></B>(TPS&nbsp;&lt;1%,&nbsp;N=22)<B></B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Arial; "><B>Low
<FONT STYLE="white-space:nowrap">PD-L1</FONT><BR></B><FONT STYLE="white-space:nowrap">(TPS&nbsp;1-49%,&nbsp;N=25)</FONT><B></B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Arial; "><B>High
<FONT STYLE="white-space:nowrap">PD-L1</FONT><BR></B>(TPS&nbsp;<FONT STYLE="font-family:Times New Roman">&#8805;</FONT>50%,&nbsp;N=4)<B></B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:SimHei; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Arial">ORR, %</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Arial; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Arial; ">54.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Arial; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Arial; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Arial; ">68.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Arial; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Arial; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Arial; ">75.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Arial; ">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:SimHei; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Arial">DCR, %</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Arial; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Arial; ">86.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Arial; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Arial; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Arial; ">92.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Arial; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Arial; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Arial; ">100</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Arial; ">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="justify"><B>Dr.</B><B></B><B>&nbsp;Atmaca, Head of Thoracic Oncology at Krankenhaus Nordwest, stated:</B> &#8220;While the
introduction of <FONT STYLE="white-space:nowrap">PD-(L)1</FONT> inhibitors, both alone and with chemotherapy, has revolutionised 1L NSCLC treatment, their limited effectiveness in cases with minimal or absent
<FONT STYLE="white-space:nowrap">PD-L1</FONT> expression highlights the ongoing need for innovative strategies that better harness the immune system against cancer. The favourable safety results and strong clinical responses seen when adding efti, a
novel immunotherapy bridging adaptive and innate immunity, to KEYTRUDA and chemotherapy are highly promising and could benefit NSCLC patients irrespective of their <FONT STYLE="white-space:nowrap">PD-L1</FONT> status.&#8221; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="justify"><B>Marc Voigt, CEO of Immutep, stated</B>: &#8220;We are increasingly confident that efti can set a new standard of care as first line treatment for <FONT
STYLE="white-space:nowrap">non-small</FONT> cell lung cancer patients through our pivotal <FONT STYLE="white-space:nowrap">TACTI-004</FONT> Phase III trial, supported by strong data from multiple clinical trials evaluating efti in lung cancer
including <FONT STYLE="white-space:nowrap">INSIGHT-003.</FONT> Efti has safely and consistently delivered impressive improvements in response rates and progression free survival compared to KEYTRUDA alone or with chemotherapy, and encouragingly
these have translated into compelling overall survival. Notably, the data is especially promising in patients with <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression under 50%, who have a high unmet need and represent more than <FONT
STYLE="white-space:nowrap">two-thirds</FONT> of the 1L NSCLC patient population.&#8221; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g62500g58i99.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="center"><B>Immutep Limited</B>, Level 32, Australia Square, 264 George Street, Sydney NSW 2000, Australia; ABN: 90 009 237 889
</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="justify">Further to the strong efficacy data from <FONT STYLE="white-space:nowrap">INSIGHT-003,</FONT> the
combination with efti continues to have a favourable safety profile. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="justify">Additionally, a Trial in Progress ePoster for the <FONT
STYLE="white-space:nowrap">TACTI-004</FONT> Phase III was presented at ESMO Congress 2025. This registrational trial is evaluating the same immunotherapy/chemotherapy combination used in <FONT STYLE="white-space:nowrap">INSIGHT-003.</FONT> This
global study will enrol approximately 756 patients with advanced/metastatic 1L NSCLC regardless of <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression (Tumour Proportion Score or TPS of <FONT STYLE="white-space:nowrap">0-100%)</FONT> with <FONT
STYLE="white-space:nowrap">non-squamous</FONT> or squamous tumours at over 150 clinical sites in over 25 countries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="justify">The poster for <FONT
STYLE="white-space:nowrap">INSIGHT-003</FONT> and the Trial in Progress ePoster for <FONT STYLE="white-space:nowrap">TACTI-004</FONT> can be found at the Posters&nbsp;&amp; Publications section of Immutep&#8217;s website. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Arial"><B>About Eftilagimod Alfa (Efti) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="justify">Efti is a novel immunotherapy
that directly activates antigen-presenting cells or APCs (e.g. dendritic cells, monocytes) via the MHC Class&nbsp;II pathway to fight cancer. As an MHC Class&nbsp;II agonist, its activation of APCs engages the adaptive and innate immune system to
initiate a broad anti-cancer immune response. This includes priming and activating cytotoxic T cells as well as generating important <FONT STYLE="white-space:nowrap">co-stimulatory</FONT> signals&nbsp;&amp; cytokines that further boost the immune
system&#8217;s ability to combat cancer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="justify">Efti is under evaluation for a variety of solid tumours including
<FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (NSCLC) in a pivotal Phase III trial called <FONT STYLE="white-space:nowrap">TACTI-004</FONT> <FONT STYLE="white-space:nowrap">(KEYNOTE-F91),</FONT> as well as head and neck squamous
cell carcinoma (HNSCC), soft tissue sarcoma, and breast cancer. Its favourable safety profile enables various combinations like with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-[L]1</FONT></FONT> immunotherapy,
radiotherapy, and/or chemotherapy. Efti has received Fast Track designation in first line HNSCC and in first line NSCLC from the United States Food and Drug Administration (FDA). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Arial"><B>About Immutep </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="justify">Immutep is a late-stage biotechnology company
developing novel immunotherapies for cancer and autoimmune disease<I>.</I> The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation <FONT STYLE="white-space:nowrap">Gene-3</FONT><B> </B><FONT
STYLE="white-space:nowrap">(LAG-3),</FONT> and its diversified product portfolio harnesses <FONT STYLE="white-space:nowrap">LAG-3&#8217;s</FONT> ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise
to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit <U>www.immutep.com</U>. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Arial; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Arial; " ALIGN="justify">Shirish Gadgeel et al. Updated Analysis From <FONT STYLE="white-space:nowrap">KEYNOTE-189:</FONT> Pembrolizumab or
Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non&#8211;Small-Cell Lung Cancer. JCO 38, 1505-1517(2020). DOI:10.1200/JCO.19.03136 </P></TD></TR></TABLE>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Arial; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Arial; " ALIGN="justify">Immutep&#8217;s Efti with KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (pembrolizumab) &amp;
Chemotherapy Achieves High Response Rates in First-Line <FONT STYLE="white-space:nowrap">Non-Small</FONT> Cell Lung Cancer&#8212;May 2025 press release </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g62500g58i99.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="center"><B>Immutep Limited</B>, Level 32, Australia Square, 264 George Street, Sydney NSW 2000, Australia; ABN: 90 009 237 889
</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Arial">KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> is a registered trademark of Merck Sharp&nbsp;&amp;
Dohme LLC, a subsidiary of Merck&nbsp;&amp; Co., Inc., Rahway, NJ, USA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Arial"><B>Australian Investors/Media: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="justify">Eleanor Pearson, Sodali&nbsp;&amp; Co. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial">+61 2 9066 4071;
<U>eleanor.pearson@sodali.com</U> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Arial"><B>U.S. Investors/Media: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial">Chris Basta,
VP, Investor Relations and Corporate Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial">+1 (631) 318 4000; <U>chris.basta@immutep.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="justify">This announcement was authorised for release by the CEO of Immutep Limited. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g62500g58i99.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="center"><B>Immutep Limited</B>, Level 32, Australia Square, 264 George Street, Sydney NSW 2000, Australia; ABN: 90 009 237 889
</P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g62500g05s89.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g62500g05s89.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1"  ^ +,# 2(  A$! Q$!_\0
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MG&3:3V"BBBD4%%%% !1110 4444 %%%% !1110 4444 %%%% !67XU\9:?\
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MA#%,EPO^D2G#IIYTY3][M:DQ_K][FES4[O0KV>(:7O:]?ZL>>R_MO+J,\/\
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,@HHHK,Z HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g62500g58i99.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g62500g58i99.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1"  A " # 2(  A$! Q$!_\0
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MP S* 0I4*V<J$ [U[!^R_P#L!>$_%'@^Q\3Z]?W?B"VU0+=6%NH:T183ROG
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MQL]QI;6<KVFF2+:RR-?6R_,),*IX0MLSWP/>NV_;%_8\3X\0IK6BM#;>)+5
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L@ "I*%*'+$,KPN+S;&QQ5>.B=W*UKVM:*Z/;U[O8]8HHHKRS]5"BBB@#_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
